 LONDON, April 19, 2021 GLOBE NEWSWIRE -- Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr Martin Murphy was appointed as non-executive chairman of its Board of Directors, effective April 15, 2021. 